Enasidenib not checked

Celgene · AG-221 · AG-221 mesylate

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
4 active
9 in total · 4 in the EU
Targets
 

What this is

How it works
Isocitrate Dehydrogenase 2 Inhibitor FDA class
Tested for
Leukemia, Myeloid, Acute
Main trialPhase 1/2
“The purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2. to investigate the safety, tolerability, and efficacy of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitrate dehydrogenase (IDH) enzyme isoforms 1 or 2 mutations, respectively.”In the company’s words, NCT02677922 on ClinicalTrials.gov
Other names
AG-221 · IDHIFA · AG-221 mesylate · AGI-12910 · AGI-12910 mesylate · CC-90007

Other drugs for Leukemia, Myeloid, Acute

All 140 drugs for Leukemia, Myeloid, Acute

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 2 Aug 2018 A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Phase 3Completed 17 Mar 2020 An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Phase 1/2Completed 3 Jun 2016 Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Phase 1/2Completed 25 Jul 2019 Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Phase 1Completed 8 Mar 2023 Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment
Phase 1Completed 22 Sep 2023 A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
Phase 3Authorised not given HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Phase 2Authorised not given IDEAL STUDY - A single-arm phase II multicenter study of IDH2 (AG-221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome
Phase 1/2Authorised not given AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Enasidenib

Following is part of Solo: you see every change to Enasidenib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in